Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
C4 Therapeutics Inc Market Cap
From what 0 stock analysts predict, the share price for C4 Therapeutics Inc (CCCC) might increase by 149.61% in the next year. This is based on a 12-month average estimation for CCCC. Price targets go from $8 to $39. The majority of stock analysts believe CCCC is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assignedCCCC 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect C4 Therapeutics Inc to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on CCCC. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of CCCC.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Etzer Darout BMO Capital | Outperform | $20 | Reiterates | Aug 6, 2024 |
| Derek Archila Wells Fargo | Equal-Weight | $8 | Maintains | May 9, 2024 |
| Bradley Canino Stifel | Buy | $14 | Maintains | May 9, 2024 |
| Terence Flynn Morgan Stanley | Equal-Weight | $8 | Maintains | Feb 26, 2024 |
| Bradley Canino Stifel | Buy | $13 | Reiterates | Feb 23, 2024 |
| Eric Joseph JP Morgan | Neutral | $6 | Upgrade | Jan 29, 2024 |
| Bradley Canino Stifel | Buy | $12 | Upgrade | Dec 13, 2023 |
| Terence Flynn Morgan Stanley | Equal-Weight | $1 | Upgrade | Nov 6, 2023 |
| Etzer Darout BMO Capital | Outperform | $16 | Maintains | Nov 3, 2023 |
| Andrew Fein HC Wainwright & Co. | Buy | $7 | Maintains | Nov 2, 2023 |
| Chi Fong B of A Securities | Neutral | $2 | Maintains | Oct 9, 2023 |
| Andrew Fein HC Wainwright & Co. | Buy | $17 | Maintains | Aug 9, 2023 |
| Gavin Clark-Gartner Evercore ISI Group | Outperform | $10 | Maintains | May 30, 2023 |
| Terence Flynn Morgan Stanley | Underweight | $3 | Maintains | May 12, 2023 |
| Andrew Fein HC Wainwright & Co. | Buy | $25 | Maintains | May 8, 2023 |
| Chi Fong B of A Securities | Neutral | $5 | Maintains | Mar 28, 2023 |
| Terence Flynn Morgan Stanley | Underweight | $5 | Maintains | Feb 27, 2023 |
| Andrew Fein HC Wainwright & Co. | Buy | $35 | Reiterates | Feb 24, 2023 |
| Eric Joseph JP Morgan | Underweight | $5 | Downgrade | Feb 24, 2023 |
| Derek Archila Wells Fargo | Equal-Weight | $9 | Maintains | Jan 3, 2023 |
When did it IPO
2020
Staff Count
145
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Andrew J. Hirsch M.B.A.
Market Cap
$441.7M
In 2023, CCCC generated $20.8M in revenue, which was a decrease of -33.25% from the previous year. This can be seen as a signal that CCCC's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 03 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - WATERTOWN, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the continued evolution of its Board of Directors with the appointment of Stephen (Steve) Fawell, Ph.D. as a director. With this appointment, Malcolm Salter has decided to retire from the Board of Directors after nearly a decade of service.
Thu, 29 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - WATERTOWN, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in fireside chats at two September investor conferences.
Thu, 01 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Preliminary Monotherapy Data from the Ongoing CFT1946 Phase 1 Trial in BRAF V600X Solid Tumors to be Presented at ESMO Congress 2024; Initiated Monotherapy Expansion Cohort in Melanoma and Combination Cohort with Cetuximab in Colorectal Cancer
Thu, 01 Aug 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.73 per share a year ago.
Tue, 16 Jul 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that preliminary data from the monotherapy dose escalation portion of the ongoing Phase 1/2 clinical trial of CFT1946, a novel BiDAC™ degrader in mutant BRAF V600 solid tumors, will be presented as a mini oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 taking place September 13 – 17, 2024 in Barcelona, Spain.
Wed, 17 Jul 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - C4 Therapeutics (CCCC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
